| 1. |
- Biglarnia, Ali-Reza, et al.
(författare)
-
Transplantation av pankreas botande alternativ vid typ 1-diabetes : [Transplantation of pancreas, a curative option for type 1 diabetes]
- 2012
-
Ingår i: Läkartidningen. - 0023-7205 .- 1652-7518. ; 109:39-40, s. 1754-1757
-
Tidskriftsartikel (refereegranskat)abstract
- In the past decade, pancreas transplantation (PTx) has become increasingly attractive as a curative treatment in patients with labile diabetes and secondary complications. In the United Kingdom, the percentage of deceased-donors utilized for PTx increased 5-fold between 2003 and 2007. The trend towards a higher number of annual pancreas transplantations is also observed in Sweden. The increasing activity and the excellent outcome are consequences of meticulous surgery, effective immunsuppression and adequate follow-up. The present report descibes the current status of PTx and shows the short- and long-term results during the last decade in Sweden.
|
|
| 2. |
- Bourdieu, Pierre, et al.
(författare)
-
Leve idrottspedagogiken : En vänbok tillägnad Lars-Magnus Engström
- 2005
-
Bok (övrigt vetenskapligt/konstnärligt)abstract
- Vem ägnar sig åt idrott? Vilken betydelse har fritiden i barns och ungdomars liv? Vad innebär hälsa i skolämnet idrott och hälsa?Leve idrottspedagogiken! tillägnas Lars-Magnus Engström. Texterna i boken speglar delar av det idrottspedagogiska forskningsområdet i Sverige, vars framväxt Lars-Magnus Engström varit den främste företrädaren för. Läsaren får här ta del av exempelvis idrottskulturen, fritidskulturen och skolans ämne idrott och hälsa. Genomgående handlar texterna om villkoren för barns och ungdomars deltagane och om de olika lärprocesser som sker i anslutning till idrottsutövning.Lars-Magnus Engström har gjort betydande insatser som forskare och lärare samt som professor vid Lärarhögskolan i Stockholm och vid Gymnastik- och idrottshögskolan. I snart fyrtion år har han arbetat med studier kring påverkans- och lärprocesser i idrott. Hans forskning har främst kretsat kring människors idrottsvanor och vilka som utvecklar en fysiskt aktiv livsstil. Idrotts- och motionsutövningar ger både ett så kallat egenvärde och investeringsvärde. Med dessa begrepp bland många andra har Lars-Magnus Engström bidragit till en fördjupad vetenskaplig förståelse av idrottskulturen.De flesta författarna har eller har haft Lars-Magnus Engström som handledare och tillhör forskningsgruppen för pedagogik, idrott och fritidskultur. Redaktörer för boken är Karin Redelius och Håkan Larsson.
|
|
| 3. |
- Christlieb, Norbert, et al.
(författare)
-
New Searches for R-Process Enhanced Stars
- 2001
-
Ingår i: Proceedings of "Astrophysical Ages and Times Scales", ASP Conference Series. - : Astronomical Society of the Pacific, San Francisco, U.S.A.. - 1583810838 ; , s. 298-300
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- We discuss strategies for the detection of additional examples of highly r-process-enhanced, ultra-metal-poor stars, such as the two presently known examples of the class, CS~22892-052, and the newly discovered CS~31082-001. We expect that a quick, modera
|
|
| 4. |
|
|
| 5. |
- Eriksson, Ulf G, et al.
(författare)
-
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran : a population model analysis
- 2003
-
Ingår i: Clinical Pharmacokinetics. - 0312-5963 .- 1179-1926. ; 42:7, s. 687-701
-
Forskningsöversikt (refereegranskat)abstract
- OBJECTIVE: Ximelagatran, an oral direct thrombin inhibitor, is rapidly bioconverted to melagatran, its active form. The objective of this population analysis was to characterise the pharmacokinetics of melagatran and its effect on activated partial thromboplastin time (APTT), an ex vivo measure of coagulation time, in orthopaedic surgery patients sequentially receiving subcutaneous melagatran and oral ximelagatran as prophylaxis for venous thromboembolism. To support the design of a pivotal dose-finding study, the impact of individualised dosage based on bodyweight and calculated creatinine clearance was examined. DESIGN AND METHODS: Pooled data obtained in three small dose-guiding studies were analysed. The patients received twice-daily administration, with either subcutaneous melagatran alone or a sequential regimen of subcutaneous melagatran followed by oral ximelagatran, for 8-11 days starting just before initiation of surgery. Nonlinear mixed-effects modelling was used to evaluate rich data of melagatran pharmacokinetics (3326 observations) and the pharmacodynamic effect on APTT (2319 observations) in samples from 216 patients collected in the three dose-guiding trials. The pharmacokinetic and pharmacodynamic models were validated using sparse data collected in a subgroup of 319 patients enrolled in the pivotal dose-finding trial. The impact of individualised dosage on pharmacokinetic and pharmacodynamic variability was evaluated by simulations of the pharmacokinetic-pharmacodynamic model. RESULTS: The pharmacokinetics of melagatran were well described by a one-compartment model with first-order absorption after both subcutaneous melagatran and oral ximelagatran. Melagatran clearance was correlated with renal function, assessed as calculated creatinine clearance. The median population clearance (creatinine clearance 70 mL/min) was 5.3 and 22.9 L/h for the subcutaneous and oral formulations, respectively. The bioavailability of melagatran after oral ximelagatran relative to subcutaneous melagatran was 23%. The volume of distribution was influenced by bodyweight. For a patient with a bodyweight of 75kg, the median population estimates were 15.5 and 159L for the subcutaneous and oral formulations, respectively. The relationship between APTT and melagatran plasma concentration was well described by a power function, with a steeper slope during and early after surgery but no influence by any covariates. Simulations demonstrated that individualised dosage based on creatinine clearance or bodyweight had no clinically relevant impact on the variability in melagatran pharmacokinetics or on the effect on APTT. CONCLUSIONS: The relatively low impact of individualised dosage on the pharmacokinetic and pharmacodynamic variability of melagatran supported the use of a fixed-dose regimen in the studied population of orthopaedic surgery patients, including those with mild to moderate renal impairment.
|
|
| 6. |
- Garcia, Lopez Ramon J, et al.
(författare)
-
Boron in very metal-poor stars
- 1998
-
Ingår i: ASTROPHYSICAL JOURNAL. - : UNIV CHICAGO PRESS. - 0004-637X. ; 500:1, s. 241-256
-
Tidskriftsartikel (refereegranskat)abstract
- We have observed the B I lambda 2497 line to derive the boron abundances of two very metal-poor stars selected to help in tracing the origin and evolution of this element in the early Galaxy: BD +23 degrees 3130 and HD 84937. The observations were conduct
|
|
| 7. |
- Gustafsson, Bengt, et al.
(författare)
-
A grid of MARCS model atmospheres for late-type stars
- 2008
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 486:3, s. 951-970
-
Forskningsöversikt (refereegranskat)abstract
- Context. In analyses of stellar spectra and colours, and for the analysis of integrated light from galaxies, a homogeneous grid of model atmospheres of late-type stars and corresponding flux spectra is needed. Aims. We construct an extensive grid of spherically-symmetric models (supplemented with plane-parallel ones for the highest surface gravities), built on up-to-date atomic and molecular data, and make it available for public use. Methods. The most recent version of the MARCS program is used. Results. We present a grid of about 104 model atmospheres for stars with 2500K <= T-eff <= 8000 K, -1 <= log g = log (GM/R-2) <= 5 (cgs) with various masses and radii, -5 <= [Me/H] <= + 1, with [alpha/Fe] = 0.0 and 0.4 and different choices of C and N abundances. This includes "CN-cycled" models with C/N=4.07 (solar), 1.5 and 0.5, C/O ranging from 0.09 to (normally) 5.0 to also represent stars of spectral types R, S and N, and with 1.0 <= xi(t) = 5km s(-1). We also list thermodynamic quantities (T, P-g, P-e, rho, partial pressures of molecules, etc.) and provide them on the World Wide Web, as well as calculated fluxes in approximately 108 000 wavelength points. Underlying assumptions in addition to 1D stratification (spherical or plane-parallel) include hydrostatic equilibrium, mixing-length convection and local thermodynamic equilibrium. We discuss a number of general properties of the models, in particular in relation to the effects of changing abundances, of blanketing, and of sphericity. We illustrate positive and negative feedbacks between sphericity and molecular blanketing. We compare the models with those of other available grids and find excellent agreement with planeparallel models of Castelli & Kurucz (if convection is treated consistently) within the overlapping parameter range. Although there are considerable departures from the spherically-symmetric NextGen models, the agreement with more recent PHOENIX models is gratifying. Conclusions. The models of the grid show considerable regularities, but some interesting departures from general patterns occur for the coolest models due to the molecular opacities. We have tested a number of approximate "rules of thumb" concerning effects of blanketing and sphericity and often found them to be astonishingly accurate. Some interesting new phenomena have been discovered and explored, such as the intricate coupling between blanketing and sphericity, and the strong effects of carbon enhancement on metal-poor models. We give further details of line absorption data for molecules, as well as details of models and comparisons with observations in subsequent papers.
|
|
| 8. |
- Gustafsson, Bengt, et al.
(författare)
-
A new MARCS Grid
- 2002
-
Ingår i: International Astronomical Union Symposium. - 1583811605 ; , s. A2-
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- An extensive grid of spherically symmetric model atmospheres of stars with 1. 2500 K <= Teff <= 8000 K, 2. -1.0 <= log g (= log GM/R2) <= 5.0 (cgs units), 3. different combinations of M and R, 4. -5 <= [A/H] <= 1, and 5. a number of CNO abundance combinat
|
|
| 9. |
|
|
| 10. |
|
|
